Medicine
-
Acquired immunodeficiency syndrome is a systemic infectious disease caused by human immunodeficiency virus infection, which could attack the bones and heart. However, the relationship between Nuclear Complex Associated 3 Homolog (NOC3L) and DEAD box helicase 17 (DDX17) and acquired immunodeficiency complicated with viral myocarditis and osteoporosis is unclear. The acquired immune deficiency dataset GSE140713, GSE147162 and the osteoporosis dataset (GSE230665), and viral myocarditis dataset (GSE150392) configuration files were generated from gene expression omnibus. ⋯ Core genes (NOC3L, WDR46, SDAD1, and DDX17) were low expressed in both acquired immunodeficiency and osteoporosis samples. Comparative toxicogenomics database analysis showed that core genes (NOC3L, WDR46, SDAD1, and DDX17) were associated with inflammation necrosis. The expressions of NOC3L and DDX17 are low in acquired immunodeficiency combined with viral myocarditis and osteoporosis.
-
Review Case Reports
When acute myocardial infarction meets renal abscess: Case report and literature review.
Acute myocardial infarction (AMI) is the leading global cause of death from cardiovascular disease, and the mortality rate increases in the presence of comorbidities such as renal abscess. The treatment of AMI combined with renal abscess is challenging, especially in combination with urinary tract obstruction, as percutaneous coronary intervention (PCI) can lead to progression of the renal abscess and deterioration of renal function. Currently, there is no consensus on the treatment of renal abscess in AMI. ⋯ The occurrence of renal abscesses is rare and may be unavoidable in those patients with preexisting structural lesions in the urinary tract where coronary angiography will increase the incidence of renal abscesses. Aggressive anti-infective therapy and drainage of pus by puncture will help the renal abscess to heal, and repeat coronary angiography has been shown to be safe in the meantime.
-
Studies have shown that uremia, renal failure and heart failure (HF) are closely related. However, whether this association reflects a causal effect is still unclear. The aim of this study was to evaluate the causal effect of uremic metabolites or toxins on HF. ⋯ Univariate and multivariate MR analyses demonstrated that lipoprotein A and apolipoprotein B were positively correlated with HF. The SNPs corresponding to these key factors were related mainly to MAP kinase activity and lipid metabolic processes. Overall, we identified 2 uremia-related exposure factors (lipoprotein A and apolipoprotein B) closely related to HF, laying a theoretical foundation for the treatment of HF with renal failure or uremia.
-
The link between gastroesophageal reflux disease (GERD) and venous thromboembolism (VTE) is not well understood. We performed a 2-sample Mendelian randomization (MR) study to explore the potential causal effect of GERD on VTE. To explore the causal relationship between genetically predicted GERD and the risk of VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT). ⋯ MR analysis results indicated that genetically predicted GERD was associated with an increased risk of venous thromboembolism (odds ratio [OR] = 1.239, 95% confidence interval [CI] = 1.146-1.339), PE (OR = 1.307, 95% CI = 1.156-1.477) and DVT (OR = 1.160, 95% CI = 1.012-1.330). Moreover, this study did not detect any heterogeneity or pleiotropy. GERD has a causal effect on venous thromboembolism, PE, and DVT.
-
Endometriosis (EMs) is a common gynecological disease accompanied by metabolic disturbances. However, the causality between metabolites and the risk of EMs remains unclear. We conducted a 2-sample Mendelian randomization (MR) analysis using the publicly available genome-wide association study (GWAS) of 486 circulating metabolites and EMs. ⋯ Additionally, there was no evidence of heterogeneity or pleiotropy of the known metabolites. Leave-one-out analysis indicated that the MR findings were robust. Our findings provide valuable circulating biomarkers as well as therapeutic targets for the screening, prevention, and treatment of EMs.